Klimstra D, Klöppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. Digestive system tumours: WHO Classification of Tumours. 5th ed. Vol. 1. IARC Press; 2019. pp. 16–9.

•• Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115–54. This manuscript describes the upcoming 2022 WHO Classification of NENS, an update to the 2019 WHO Guidelines. These are key guidelines that set the standards for pathology reporting for NENs.

Article  CAS  PubMed  Google Scholar 

Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–22.

Article  PubMed  PubMed Central  Google Scholar 

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

Article  PubMed  PubMed Central  Google Scholar 

Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–4.

Article  CAS  PubMed  Google Scholar 

Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep. 2021;23(4):43.

Article  PubMed  PubMed Central  Google Scholar 

Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, et al. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database. Eur J Surg Oncol. 2018;44(10):1628–33.

Article  PubMed  Google Scholar 

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

Article  PubMed  Google Scholar 

Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.

Article  PubMed  PubMed Central  Google Scholar 

Bordi C. Endocrine tumours of the stomach. Pathol Res Pract. 1995;191(4):373–80.

Article  CAS  PubMed  Google Scholar 

Patel N, Barbieri A, Gibson J. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas. Surg Pathol Clin. 2019;12(4):1021–44.

Article  PubMed  Google Scholar 

Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994–1006.

Article  CAS  PubMed  Google Scholar 

Sculco D, Bilgrami S. Pernicious anemia and gastric carcinoid tumor: case report and review. Am J Gastroenterol. 1997;92(8):1378–80.

CAS  PubMed  Google Scholar 

Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer. 1994;73(8):2053–8.

Article  CAS  PubMed  Google Scholar 

Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90(3):338–52.

CAS  PubMed  Google Scholar 

Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010;24(3):355–70.

Article  CAS  PubMed  Google Scholar 

Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist. 2014;19(1):44–50.

Article  PubMed  Google Scholar 

Chen WC, Warner RR, Ward SC, Harpaz N, Divino CM, Itzkowitz SH, et al. Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience. Dig Dis Sci. 2015;60(4):996–1003.

Article  CAS  PubMed  Google Scholar 

Exarchou K, Stephens NA, Moore AR, Howes NR, Pritchard DM. New Developments in Gastric Neuroendocrine Neoplasms. Curr Oncol Rep. 2022;24(1):77–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCarthy DM. Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids-what is the relationship? Int J Mol Sci. 2020;21(2):662. 

• Rais R, Trikalinos NA, Liu J, Chatterjee D. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use. Arch Pathol Lab Med. 2022;146(3):366–71. Retrospective clinicopathologic study examining the association of long-term PPI use and development of a new type of gastric NEN.

Article  CAS  PubMed  Google Scholar 

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36(12):1761–70.

Article  PubMed  Google Scholar 

Laffi A, Lania AGA, Ragni A, Di Vito V, Liccardi A, Rubino M, Sesti F, Colao A, Faggiano A, On Behalf Of The Nike Group. Gastric neuroendocrine tumors (g-NETs): A systematic review of the management and outcomes of type 3 g-NETs. Cancers (Basel). 2023;15(8):2202.

Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(7):839–68.

Article  CAS  PubMed  Google Scholar 

Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine. 2006;85(6):295–330 (Baltimore).

Article  CAS  PubMed  Google Scholar 

Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4(4):167–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25(17):4012.

Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer staging manual. 8th ed. New York: Springer; 2017.

Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RC 2nd. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009;16(1):51–60.

Article  PubMed  Google Scholar 

Xie JW, Li P, Wang JB, Lin JX, Lu J, Chen QY, et al. Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment. J Cancer Res Clin Oncol. 2018;144(12):2391–7.

Article  PubMed  Google Scholar 

Yang T, Fong ZV, Pak L, Wang SJ, Wei J, Wang J. A Modified T-Stage Classification for Gastric Neuroendocrine Tumors. J Surg Res. 2022;270:486–94.

Article  PubMed  Google Scholar 

Zhang R, Guo Y, Wang Y, Hu L, Fang C, Yang Y, et al. Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system. Cancer Med. 2023;12(6):6623–36.

Article  CAS  PubMed  Google Scholar 

Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168(2):185–93.

Article  CAS  PubMed  Google Scholar 

Lenti MV, Rugge M, Lahner E, Miceli E, Toh BH, Genta RM, et al. Autoimmune gastritis Nat Rev Dis Primers. 2020;6(1):56.

Article  PubMed  Google Scholar 

Merola E, Sbrozzi-Vanni A, Panzuto F, D’Ambra G, Di Giulio E, Pilozzi E, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95(3):207–13.

Article  CAS  PubMed  Google Scholar 

Uygun A, Kadayifci A, Polat Z, Yilmaz K, Gunal